Abstract CT110: Randomized phase II study of duligotuzumab + FOLFIRI versus cetuximab + FOLFIRI in 2nd-line patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC)

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study)

Medical Oncology ◽

10.1007/s12032-019-1254-4 ◽

2019 ◽

Vol 36 (6) ◽

Cited By ~ 1

Author(s):

Naoki Nagata ◽

Hiromichi Maeda ◽

Keiichiro Ishibashi ◽

Keiji Hirata ◽

Akitaka Makiyama ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Wild Type ◽

Open Label ◽

PEAK: A randomized phase II study to compare the efficacy of panitumumab plus mFOLFOX6 to bevacizumab plus mFOLFOX6 in patients (pts) with previously untreated, unresectable metastatic colorectal cancer (mCRC) expressing wild-type KRAS.

10.1200/jco.2010.28.15_suppl.tps189 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. TPS189-TPS189

Author(s):

L. S. Schwartzberg ◽

V. J. Wagner

Keyword(s):

Colorectal Cancer ◽

Unresectable Metastatic Colorectal Cancer

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

Randomized Phase Ii ◽

Randomized phase II study of regorafenib followed by cetuximab versus reverse sequence for wild-type KRAS metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and irinotecan (REVERCE).

10.1200/jco.2014.32.15_suppl.tps3662 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS3662-TPS3662

Author(s):

Kohei Shitara ◽

Kentaro Yamazaki ◽

Hiroyuki Uetake ◽

Takeshi Kato ◽

Eiji Oki ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

Randomized Phase Ii ◽

Reverse Sequence ◽

Previously Treated

A randomized phase II study (B2151005) of the intravenous phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor PF-05212384 plus irinotecan versus cetuximab plus irinotecan in patients with wild-type KRAS metastatic colorectal cancer (mCRC).

10.1200/jco.2014.32.15_suppl.tps3649 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS3649-TPS3649 ◽

Cited By ~ 2

Author(s):

Josep Tabernero ◽

Nicoletta Brega ◽

Craig Davis ◽

Ashwin Gollerkeri ◽

Kristen Pierce ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Mtor Inhibitor ◽

Phase Ii Study ◽

Mammalian Target Of Rapamycin ◽

Target Of Rapamycin ◽

Wild Type ◽

Phosphatidylinositol 3 Kinase ◽

Predictive value of primary tumor location: Results from randomized phase II study of panitumumab + irinotecan versus cetuximab + irinotecan in patients with KRAS exon2 wild-type metastatic colorectal cancer (WJOG6510G)

Annals of Oncology ◽

10.1093/annonc/mdx393.109 ◽

2017 ◽

Vol 28 ◽

pp. v198

Author(s):

T. Tamura ◽

D. Sakai ◽

N. Sugimoto ◽

S. Tokunaga ◽

A. Tsuji ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Primary Tumor ◽

Predictive Value ◽

Phase Ii Study ◽

Tumor Location ◽

Wild Type ◽

Primary Tumor Location ◽

The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients

BMC Cancer ◽

10.1186/s12885-018-4001-x ◽

2018 ◽

Vol 18 (1) ◽

Cited By ~ 3

Author(s):

Francesca Battaglin ◽

Marta Schirripa ◽

Federica Buggin ◽

Filippo Pietrantonio ◽

Federica Morano ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

First Line ◽

Randomized Phase Ii ◽

Colorectal Cancer Patients

LBA-09 Cetuximab beyond progression in RAS wild type (WT) metastatic colorectal cancer (mCRC): the CAPRI-GOIM randomized phase II study of FOLFOX versus FOLFOX plus cetuximab

Annals of Oncology ◽

10.1093/annonc/mdv262.09 ◽

2015 ◽

Vol 26 ◽

pp. iv120 ◽

Cited By ~ 6

Author(s):

F. Ciardiello ◽

N. Normanno ◽

E. Martinelli ◽

T. Troiani ◽

C. Cardone ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

Randomized phase II study of first-line FOLFOX plus panitumumab (pan) versus 5FU plus pan in elderly RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts): The PANDA study.

10.1200/jco.2016.34.15_suppl.tps3627 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS3627-TPS3627

Author(s):

Roberto Moretto ◽

Francesca Battaglin ◽

Carlotta Antoniotti ◽

Federica Buggin ◽

Laura Delliponti ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

First Line ◽

UCGI 28 Panirinox: A randomized phase II study assessing Panitumumab + FOLFIRINOX or mFOLFOX6 in RAS and BRAF wild type metastatic colorectal cancer patients (mCRC) selected from circulating DNA analysis

Annals of Oncology ◽

10.1093/annonc/mdy281.159 ◽

2018 ◽

Vol 29 ◽

pp. viii204

Author(s):

T. Mazard ◽

F. Ghiringhelli ◽

C. Mollevi ◽

E. Assenat ◽

C. Gavoille ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Dna Analysis ◽

Phase Ii Study ◽

Circulating Dna ◽

Wild Type ◽

Randomized Phase Ii ◽

Colorectal Cancer Patients

Rationale and study design of the PARERE trial: Randomized phase II study of panitumumab re-treatment followed by regorafenib versus the reverse sequence in RAS and BRAF wild-type chemo-refractory metastatic colorectal cancer patients

Clinical Colorectal Cancer ◽

10.1016/j.clcc.2021.07.001 ◽

2021 ◽

Author(s):

Roberto Moretto ◽

Daniele Rossini ◽

Iolanda Capone ◽

Alessandra Boccaccino ◽

Federica Perrone ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Study Design ◽

Phase Ii Study ◽

Wild Type ◽

Randomized Phase Ii ◽

Reverse Sequence ◽

Colorectal Cancer Patients